Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 676 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... March 28, 2025 Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions February 16, 2024 Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... January 30, 2024 Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 Load more HOT NEWS Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... Seeing a Promising Future for Progress against Childhood Cancer
